Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| LONG 10-01 | Other Identifier | University Hospital Ghent |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Nationaal Kankerplan | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC). Selected patients unwilling or unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy. This has shown to result in a long term local disease control rate and a high cancer specific survival.
The current trial addresses the issue if progression free survival (PFS) in patients treated with radiotherapy can be predicted by a multi-variate model derived from a composite of bio-imaging and biomarkers
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Radiation therapy | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| hypofractionated radiation therapy | Radiation | hypofractionated radiation therapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| development and validation of a multi-variate predictive model | To develop and validate a multi-variate predictive model based on bio-imaging and biomarkers for progression)free survival from 2 to 5 years. | from 2 to 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| the clinical response and complication rate | from 2 to 5 years | |
| local, regional or distant failure | from 2 to 5 years | |
| progression free survival |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jan Van Meerbeeck, MD,PhD | University Hospital, Ghent | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Ghent | Ghent | Belgium |
Not provided
| Label | URL |
|---|---|
| Website of University Hospital Ghent | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| from 2 to 5 years |
| disease specific overall survival | from 2 to 5 years |